Other languages Creative Medical Technology Holdings, Inc. Other OTC

Equities

CELZ

US22529Y2000

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Creative Medical Successfully Generated Human Ipsc-Derived Islet Cells That Produce Human Insulin	24/06
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin	24/06
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/03
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access	07/03
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise	07/03
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures	06/03
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony	06/03
Top Premarket Gainers	06/03
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem	20/12
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain	10/23/10
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem? (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain	19/23/19
Top Premarket Gainers	13/23/13
Top Premarket Gainers	21/23/21
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12
Top Premarket Decliners	16/23/16
Creative Medical Technology Holdings, Inc. announces an Equity Buyback for $2 million worth of its shares.	12/23/12
Creative Medical Technology Holdings, Inc. authorizes a Buyback Plan.	12/23/12
Creative Medical to Trade on 1-for-10 Reverse Stock-Split Basis Starting Monday	09/23/09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Creative Medical Technology Holdings, Inc. Other OTC

Equities

CELZ

US22529Y2000

Other languages

Filters